Evidence map›Paper›PMID 37350146›Full record

ArticleJournal of gynecologic oncology2023

A comparison of concurrent chemoradiotherapy and radical surgery in patients with specific locally advanced cervical cancer (stage IB3, IIA2, IIICr): trial protocol for a randomized controlled study (C-CRAL trial).

Junjun Qiu, Shugen Sun, Qinqin Liu, Jie Fu, Yan Huang, Keqin Hua

Open access · diamondAbstract readClinical Trial Protocol
In one paragraph

Article in Journal of gynecologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Junjun Qiu *Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.ORCID 0000-0002-2063-2684
Shugen Sun *Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.ORCID 0000-0002-2078-5357
Qinqin LiuDepartment of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.ORCID 0000-0001-9299-453X
Jie FuDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.ORCID 0000-0002-3183-453X
Yan HuangDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0001-8811-7462
Keqin HuaDepartment of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. huakeqinjiaoshou@163.com.ORCID 0000-0001-5359-8841
Obstetrics and Gynecology Hospital of Fudan University · CNFudan University Shanghai Cancer Center · CNShanghai Jiao Tong University · CN

Funding

Clinical Research Plan of SHDC SHDC2020CR1045BScience and Technology Commission of Shanghai Municipality 22Y31900500
6 · The paper itself

Abstract

backgroundAt present, clinical dilemma remains to be solved in terms of therapy-choices for specific locally advanced cervical cancer (LACC) patients: 1) Although concurrent chemoradiotherapy (CCRT) is recommended as the first choice for them, many patients, influenced by the Chinese culture, prefer to choose radical surgery (RS) as their primary treatment. The difference between the 2 therapies in improving patient prognosis is still unknown. 2) Laparoscopy has been questioned since the noted Laparoscopic Approach to Cervical Cancer trial. Nevertheless, clinical research on laparoscopic surgery under the strict tumor-free principle is still underway globally, therefore whether laparoscopic surgery can be used for specific LACC is also an urgent issue to be explored.

methodsA multi-center, randomized controlled study is designed to investigate the effect of different treatment strategies on the prognosis and quality of life (QoL) in patients with specific locally LACC. A total of 402 patients will be enrolled over a period of 3 years. Eligible patients will be randomized (3:1) to either RS group or CCRT group. Patients assigned to RS group will be randomized (1:2) to the abdominal RS group or laparoscopic RS group. All patients will then be followed-up for 5 years. The primary end point is the 2-year progression-free survival (PFS). The secondary end points include 5-year PFS, 2-year overall survival (OS), 5-year OS, adverse events caused by RS or CCRT and QoL.

trial registrationChinese Clinical Trial Registry Identifier: ChiCTR2000041315.

Indexed as

AdenocarcinomaCarcinoma, Squamous CellUterine Cervical NeoplasmsChemoradiotherapyFemaleHumansMulticenter Studies as TopicNeoplasm StagingQuality of LifeRandomized Controlled Trials as TopicRetrospective StudiesChemoradiotherapyHysterectomyLaparoscopyPrognosisUterine Cervical Neoplasms

Identifiers

PMID37350146
PMCPMC10482577
OpenAlexW4381681604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.